Back to Journals » OncoTargets and Therapy » Volume 11

Long-term survival with transarterial chemoembolization and radioembolization in a patient with cancers of unknown primary

Authors Aktas G, Kus T, Metin T, Kervancioglu S, Elboga U

Received 3 October 2017

Accepted for publication 6 February 2018

Published 4 April 2018 Volume 2018:11 Pages 1885—1889


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Ingrid Espinoza

Gokmen Aktas,1 Tulay Kus,2 Taylan Metin,3 Selim Kervancioglu,4 Umut Elboga5

1Department of Internal Medicine, Division of Medical Oncology, School of Medicine, University of Kahramanmaras Sutcu Imam, Kahramanmaraş, Turkey; 2Division of Medical Oncology, Adiyaman Training and Research Hospital, Adiyaman, Turkey; 3Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey; 4Department of Radiology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey; 5Department of Nuclear Medicine, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey

Cancers of unknown primary (CUP) are histologically proven metastatic malignant tumors without an identified primary site before treatment. The common characteristics are early dissemination, lower response to chemotherapy and poor prognosis with short life expectancy. Treatment was directed according to the presence of localized or disseminated disease. The most frequent site of metastasis is the liver, which is a suitable target organ for arterial-directed therapies. We report a case of 53-year-old woman who was diagnosed with CUP and suspected with intracellular cholangiocellular carcinoma (ICC), presented with a very large, unresectable, chemotherapy-refractory hepatic mass and treated with transarterial chemoembolization and transarterial radioembolization and surprisingly followed for 48 months with minimally progressive and stable disease. Arterial-directed therapies, an important therapeutic option in unresectable liver tumors, can provide survival benefit even for ICC and CUP which are very large in size.

Keywords: cancers of unknown primary, TACE, TARE

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]